Alnylam Pharmaceuticals Stock News

Michael Yee, Jefferies, on whether there's more M&A to come in the biotech space. With CNBC's Melissa Lee and the Fast Money traders, Tim Seymour, Steve Grasso, Pete Najarian and Karen Finerman.

Alnylam Pharmaceuticals, Inc. ALNY announced that it has submitted a supplemental new drug application (sNDA) to the FDA and a Type II filing variation to the European Medicines Agency (EMA) for its RNAi therapeutic, lumasiran for the reduction of plasma oxalate in the treatment of patients with advanced primary hyperoxaluria type 1 (PH1). The latest [] The post Alnylam (ALNY) Files for Oxlumo Label Expansion in US & EU appeared first on UK Stocks, Forex, Commodities, Crypto, Live Market News- Daily Forex News .

Alnylam (ALNY) files regulatory applications to the FDA and the EMA, seeking approval for a new indication of Oxlumo for the treatment of advanced primary hyperoxaluria type 1.

Biotech stocks are risky investments and to make a profit informed decision-making is needed. BofA Securities announced its top mid-cap biopharma picks in a note released Tuesday.

(RTTNews) - Alnylam Pharmaceuticals Inc. (ALNY) said that it has submitted a supplemental New Drug Application or sNDA to the U.S. Food and Drug Administration and Type II Filing Variation to the European Medicines Agency for lumasiran, an investigational RNAi therapeutic targeting hydroxyacid oxidase 1 (HAO1) - the gene encoding glycolate…

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today the submission of a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) and Type II Filing Variation to the European Medicines Agency (EMA) for lumasiran, an investigational RNAi therapeutic targeting hydroxyacid oxidase 1 (HAO1) the gene encoding glycolate oxidase (GO) for the reduction of plasma oxalate in the treatment

Antisense & RNAi Therapeutics Market 2021 report helps the clients to take business decisions and to understand strategies of major players in the industry. The report also calls for market- driven results deriving feasibility studies for client needs. Market Insights

Equities research analysts expect Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) to post sales of $232.16 million for the current fiscal quarter, Zacks reports. Seven analysts have provided estimates for Alnylam Pharmaceuticals’ earnings, with the lowest sales estimate coming in at $214.75 million and the highest estimate coming in at $244.40 million. Alnylam Pharmaceuticals posted sales of $163.56 […] The post Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Expected to Announce Quarterly Sales of $232.16 Million appeared first on ETF Daily News .

Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY)s traded shares stood at 0.39 million during the last session, with the companys beta value hitting 0.91. At the close of trading, the stocks price was $173.65, to imply an increase of 0.68% or $1.18 in intraday trading. The ALNY shares 52-week high remains $212.00, putting it -22.08% down since that Alnylam Pharmaceuticals Inc. (NASDAQ: ALNY) Gain Of 28.9% Compared To 52-Week Low; YTD Rise 33.61% What Should You Do Now? Read More »

They may deliver major gains down the road.

RNA based mostly medicine Market has garnered vital attention within the recent years because of its potential to treat type of chronic diseases like cancer, diabetes, AIDS, infectious disease and sure vas conditions. RNA Based Therapeutics Market is expected to garner

Related Stocks: AMGN , GH , IDXX , ALNY , NVAX , SRPT , ICLR , BHVN , CTLT , CRBU , AZN , RLYB , ABT , ASND , NBIX , DXCM , ARNA , ARGX , DCPH , BBIO , RMD , BPMC , ALLK , IOVA ,

NEW YORK--(BUSINESS WIRE)--Yarrow Biotechnology, Inc., an RTW-incubated company developing antisense oligonucleotide (ASO) therapeutics for severe, genetically defined CNS diseases, today announced the appointment of Dr. Mark T. Keating as Chief Scientific Officer. Dr. Keating joins Yarrow from Alnylam Pharmaceuticals, where he served as Vice President and Distinguished Fellow and led multiple programs for extrahepatic delivery of ASO therapeutics, including for CNS disorders. Im so pleased t

Koshinski Asset Management Inc. bought a new stake in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) during the 3rd quarter, HoldingsChannel reports. The firm bought 235 shares of the biopharmaceutical companys stock, valued at approximately $44,000. A number of other large investors have also added to or reduced their stakes in ALNY. IFP Advisors Inc grew []

SVB Leerink reaffirmed their hold rating on shares of Alnylam Pharmaceuticals (NASDAQ:ALNY) in a report published on Wednesday, Price Targets.com reports. ALNY has been the topic of a number of other reports. HC Wainwright boosted their price target on shares of Alnylam Pharmaceuticals from $235.00 to $250.00 and gave the stock a buy rating in []